Investigators of the phase 3 KESTREL trial recruited 823 patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Population-based study demonstrated an association between patient-reported outcomes and ED visits/unplanned hospitalizations among patients with head and neck cancer.
Researchers sought to determine the effect of PDC on venous thromboembolism and bleeding events in patients with HNC undergoing surgery.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
